Original from: Genomeweb
Co-Diagnostics said on Wednesday that it has signed definitive agreements to acquire privately held biotech firms Idaho Molecular and Advanced Conceptions for nearly $50 million in stock and warrants.
Under the terms of the agreements, Salt Lake City-based Co-Diagnostics will acquire the two companies for roughly 4.72 million shares of newly issued common stock and 465,000 common warrants.
During late morning trading on the Nasdaq, shares of Co-Diagnostics were up $.57 at $9.61.
Co-Diagnostics said it has been working with Idaho Molecular and Advanced Conceptions, which are also based in Salt Lake City, on the development of its upcoming sample-to-answer YourTest at-home/point-of-care diagnostic device, which is based on the firm's Eikon PCR platform.
Co-Diagnostics said the acquisitions, expected to close before the end of the year, will provide it with the rights to all existing and future assets and intellectual property related to the technology as it begins principle and large-scale manufacturing of the YourTest device and an initial COVID-19 test.
In August, Co-Diagnostics reported a 14 percent year-over-year increase in second quarter revenues on demand for its Logix Smart COVID-19 test.
Source: Co-Diagnostics to Acquire Idaho Molecular, Advanced Conceptions for up to $50M
Copyright © 2024 GL events Ruihe (Shanghai) Exhibition Co., Ltd. All Rights Reserved. ( 沪ICP备12004745号-1 )
We deliver the latest IVD news straight to your inbox. Stay in touch with CACLP News.
sign-up for our newsletter today.
To ensure our newsletter hit your inbox, make sure to add @caclp.com to your safe senders list. And, as always, feel free to contact
us with any questions and thanks again for subscribing.